Clinical Observation of Shenyi Capsule Combined with Bevacizumab in the Treatment of Advanced Ovarian Cancer to Improve the Immune Function of Patients

This study was to investigate the short-term effect of Shenyi capsule combined with Bevacizumab in treating advanced ovarian cancer and the effect of peripheral blood Th1/Th2 cytokines.Eighty-eight advanced ovarian cancer cases from our hospital were randomly divided into treatment group and control group with 44 in each group referring to number table method.Both groups were given with chemotherapy of Paclitaxel combined with cisplatin. Control group was treated with Bevacizumab 1 h after chemotherapy.On basis of control group, treatment group was treated with Shenyi capsule. After 9 weeks,the short-term effect, adverse drug reaction, peripheral blood level of Th1/Th2, and serum levles of interferon-γ (IFN-γ), interleukin-2 (IL-2), IL-4, and IL-10 were compared for both groups. The results showed that the short-term effect of treatment group was obviously higher than control group, and the incidence of leukopenia and thrombocytopenia in the treatment group was significantly lower than that in the control group (P<0.05). Peripheral blood level of Th1 and Th1/Th2 and serum levels of IFN-γ and IL-2 of treatment group were obviously higher,while Th2 and IL-4 and IL-10 were less, than those of the control group after treatment (P<0.01). This study confirmed that Shenyi capsule combined with Bevacizumab in treating advanced ovarian cancer can increase the short-term effect, decrease the adverse drug reaction and the regulation of Thl/Th2 cytokines may be related with the efficacy.

CSTR: 32200.14.cjcb.2019.09.0013